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Abstract
Background: Early in mammalian brain development cell proliferation generates a population of
progenitor cells whose subsequent divisions produce increasing numbers of postmitotic neurons.
Pax6 affects both processes and it has been suggested that this changing role is due at least in part
to changes in the relative concentrations of its two main isoforms, (i) Pax6 and (ii) Pax6(5a), created
by insertion of a 42 bp exon (exon 5a) into one of the two DNA-binding domains. Crucially,
however, no previous study has determined whether the ratio between Pax6  and  Pax6(5a)
transcripts alters during mammalian neurogenesis in vivo.
Results: Using RNase protection assays, we show that Pax6 transcripts are 6–10 times more
prevalent than Pax6(5a)  transcripts early in neurogenesis in the murine telencephalon,
diencephalon and hindbrain and that the ratio later falls significantly to about 3:1 in these regions.
Conclusion: These changes in vivo are similar in magnitude to those shown previously to alter
target gene activity in vitro and might, therefore, allow the single mammalian Pax6 gene to carry out
different functions at different times in mammalian brain development.
Background
Pax6 is expressed in the developing eye and brain, where
it affects both progenitor cell production and neuronal
differentiation [1-5]. The Pax6 protein contains two DNA
binding domains, a paired domain (PD) and a paired-
type homeodomain (HD) (Fig. 1A). The PD consists of
two separate helix-turn-helix motifs, termed PAI and RED,
which act on different target sequences [6]. The best char-
acterised  Pax6  alternative splicing event, involving the
insertion of a 42 bp exon (exon 5a) into the PAI sub-
domain of the PD, results in two major Pax6 isoforms
[Pax6 and Pax6(5a)] with different DNA-binding proper-
ties. In vitro studies have shown that the PAI subdomain
of Pax6 binds preferentially to a consensus sequence
(P6CON) [7] but that PAI subdomain disruption in
Pax6(5a) allows the RED subdomain to bind an alterna-
tive sequence (5aCON) [6].
Pax6 affects early progenitor cell proliferation and later
neuronal differentiation in the developing brain [4,5].
This changing role might be due at least in part to a shift
in the relative concentrations of Pax6 and Pax6(5a) dur-
ing development but there has been no previous report of
such alterations during neurogenesis in the brain in vivo.
We anticipated that even relatively small changes in the
Pax6 : Pax6(5a) ratio might be important since stronger
effects on gene activity via  P6CON and 5aCON are
observed if Pax6  and  Pax6(5a)  are introduced into
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Detection of Pax6 and Pax6(5a) Figure 1
Detection of Pax6 and Pax6(5a). (A) Riboprobe design. The ssRNA antisense riboprobe used to detect both Pax6 and Pax6(5a) 
spans the Pax6 mRNA from exon 3 to exon 5a. Two protected fragments are produced, Pax6 (218nt) and Pax6(5a) (247nt). 
The PD- and HD-coding regions are represented above the Pax6 mRNA sequence, which is shown to scale. Grey and black 
bars are exons. Broken line shows part of the riboprobe derived from the vector. (B) Example of an RNase protection assay 
showing GAPDH and Pax6 signal detected in total RNA from E12.5 eye (E), diencephalon (D) and telencephalon (T). 1 µg total 
RNA was used in each sample. Central lane is a DNA ladder, which allows approximate sizing of bands (fragment sizes are indi-
cated above bands). (C) Quantification of RNase protection assays. Pax6 (lower band) and Pax6(5a) (upper band) in the telen-
cephalon, diencephalon and eye at E12.5 and E18.5. Gel images and densitometric traces of bands are shown. Level of 
background estimated using the rolling disk method (Quantity One software, Biorad) is indicated on each trace.BMC Developmental Biology 2005, 5:13 http://www.biomedcentral.com/1471-213X/5/13
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cultured cell lines at ratios of 1:1 or 8:1 than at ratios of
2:1, 4:1 or 16:1 [8]. We selected a direct method for quan-
tification of the ratio (RNase protection assays) and car-
ried out multiple assays so as to obtain statistically
analysable data on key Pax6-expressing brain tissues at a
range of ages throughout neurogenesis. We found changes
in the ratio similar in magnitude to those shown previ-
ously to alter target gene activity in vitro.
Results and Discussion
RNase protection assays were carried out on tissues dis-
sected from wild type mouse embryos aged E12.5-E18.5
and quantified by densitometry (Fig. 1). The Pax6  :
Pax6(5a) ratio varied throughout neurogenesis in the tel-
encephalon, diencephalon and hindbrain, following a
similar pattern in each (Table 1). In the telencephalon, the
ratio was about 6:1 early in neurogenesis, at E12.5, but
was significantly lower (about 2:1) at each subsequent age
(p < 0.05–p < 0.01; Table 1). In the diencephalon and
hindbrain, ratios were about 8:1 and 10:1 at E12.5 but
were lower (about 2:1 to 4:1) from E14.5-E18.5 (Table 1);
these decreases were statistically significant when data
from all three age groups were combined (p < 0.05 for
both tissues). Combining results from the telencephalon,
diencephalon and hindbrain showed a significant fall in
the Pax6 : Pax6(5a) ratio between E12.5 and E14.5, from
approximately 8:1 to 3:1 (p < 0.05), with a further slight
decrease at E16.5 and E18.5 (p < 0.01; Table 1). Data on
the Pax6 : Pax6(5a) ratio in the eye at E12.5-E18.5 did not
show the same trend (Table 1). Ratios varied from about
10:1 at E14.5 to about 4:1 at E18.5 but none of the differ-
ences were statistically significant. Although we did not
detect significant changes in the eye, it is possible that
non-synchronised changes in the ratio do occur within its
component Pax6-expressing neural and non-neural tis-
sues (cornea, lens and retina). Neither Pax6 nor Pax6(5a)
was detected in samples from the feet.
There is evidence that Pax6 and Pax6(5a) have different
functions in vivo in both vertebrates [9-11] and inverte-
brates [12,13]. Studies of Pax6- and Pax6(5a)-related
genes in Drosophila melanogaster, ey/ toy and eyg/ toe, have
shown that they promote, respectively, differentiation
and proliferation of eye precursor cells [12,13].
Overexpression of Pax6 and Pax6(5a) can alter the expres-
sion of different sets of genes in mammals [10,11]. Mam-
malian brain cells reduce their proliferation in response to
overexpression of Pax6 or Pax6(5a) and increase their
neurogenesis in response to overexpression of Pax6 [9]. It
is possible that a reduction in the Pax6 : Pax6(5a) mRNA
ratio from E14.5 is involved in programming progenitor
cells to initiate processes that occur later in embryogene-
sis. Such processes are potentially numerous; they might,
for example, include the transition from predominantly
neurogenesis to the major phase of gliogenesis or the
development of specific sets of later-generated neurones
such as the superficial layers of the cerebral cortex.
Conclusion
We conclude that the Pax6 : Pax6(5a) ratio falls in the tel-
encephalon, diencephalon and hindbrain during neuro-
genesis and, moreover, the magnitude of the change is in
the range that alters target gene expression in vitro [8]. This
finding allows the possibility that changes in the relative
expression levels of isoforms of a single Pax6 gene might
result in changes in the functions of this gene in mamma-
lian brain development.
Methods
For each RNase protection assay, wild-type mice (CD-1)
were time-mated [the day of conception was designated
embryonic day 0.5 (E0.5)] and killed on E12.5, E14.5,
E16.5 or E18.5. The telencephalon, diencephalon, hind-
brain, eyes and feet (used as a Pax6 non-expressing con-
trol tissue) were dissected from each embryo. Tissues from
multiple embryos were combined so as to obtain suffi-
cient material for each assay. Total RNA was isolated from
tissue snap-frozen in liquid nitrogen, its integrity was
checked by agarose gel electrophoresis and its concentra-
tion was measured using a fluorimeter. The riboprobe was
designed to span the Pax6 mRNA from exon 3 to exon 5a
so as to protect Pax6 and Pax6(5a) mRNAs (Fig. 1A). Oli-
Table 1: Mean Pax6: Pax6(5a) ratios ± SEMs. "Combined" data are from telencephalon, diencephalon and hindbrain considered 
together at each age. For each tissue and for combined brain tissues, significant differences between values at E12.5 and values at 
subsequent ages are shown (unpaired Student's t-tests; * = p < 0.05, ** = p < 0.01). Numbers of individual assays are indicated in 
brackets.
E12.5 E14.5 E16.5 E18.5
Telencephalon 6.25 +/- 0.68 (5) 2.12 +/- 0.77** (2) 2.63 +/- 1.52* (3) 2.53 +/- 0.37** (4)
Diencephalon 9.72 +/- 3.37 (3) 3.63 +/- 0.63 (3) 1.41 (1) 3.00 +/- 0.63 (2)
Hindbrain 7.66 +/- 3.68 (4) 3.87 +/- 1.62 (2) 1.66 +/- 0.35 (2) 2.23 +/- 0.12 (3)
Combined 7.59 +/- 1.41 (12) 3.27 +/- 0.55* (7) 2.10 +/- 0.72** (6) 2.53 +/- 0.21** (9)
Eye 6.81 +/- 2.08 (4) 9.52 +/- 3.64 (3) 5.95 +/- 1.90 (3) 3.55 +/- 1.30 (3)Publish with BioMed Central    and   every 
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gonucleotides 5'-AAG TGG ACG TAT ATC CCA GTT CTC-
3' and 5'-AGC ACC TGG ACT TTT GCA TC-3' were used to
amplify sequence from mouse Pax6 cDNA. Pax6 cDNA
was cloned into pCR-BluntII-TOPO and sequenced across
the Pax6 insert in both directions to identify clones with
Pax6 sequence in the appropriate orientation to generate
antisense probe. The plasmid pTRI-GAPDH (Ambion)
was used for synthesis of a murine glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) riboprobe. Riboprobe
synthesis was carried out using the Maxiscript SP6 in vitro
transcription kit (Ambion) in the presence of 40 µCi α -
32P-UTP 800 Ci/mmol (Amersham). Riboprobes were
purified using a MicroSpin G25 column (Amersham
Biosciences).
RNase protection assays were performed on 1 µg total
RNA from E12.5 and E14.5 embryonic tissues, or 4 µg
total RNA from E16.5 and E18.5 embryonic tissues, using
the Hyb Speed kit (Ambion). The quality the undigested
full-length riboprobe was examined and that of all total
RNA samples was assessed using a GAPDH riboprobe (e.g.
Fig. 1B). Products were resolved on 6% polyacrylamide, 8
M urea gels that were then fixed (15% methanol, 5% ace-
tic acid for 30 minutes), dried and exposed to film with an
intensifying screen. Where GAPDH signal was weak, this
was a sign that protein or DNA contamination had led to
inaccurate RNA quantification, and these samples were
excluded from subsequent analyses. Gel bands were quan-
titated using a GS-710 densitometer and the Quantity
One software package (BioRad: background subtraction
was performed using the rolling disk method [14]; Fig.
1C). Each assay was repeated several times (n values for
the number of assays for each tissue at each age are in
Table 1).
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